Strados Labs, a medical technology company, is excited to announce a new partnership with Trialogics, a clinical trial software and logistics provider.
by Strados Labs | Oct 31, 2024 | Press Releases
Strados Labs, a medical technology company, is excited to announce a new partnership with Trialogics, a clinical trial software and logistics provider. This collaboration will leverage Trialogics’ comprehensive logistical expertise to streamline the distribution and delivery of Strados Labs’ RESP® Biosensors to clinical trial sites internationally.
Strados Labs’ FDA-cleared RESP Biosensor continuously captures lung sounds in patients remotely to objectively identify changes in symptoms such as coughing and wheezing. The device is used by drug developers to measure treatment response and endpoints in Phase I-IV clinical trials located in multiple parts of the world including Asia, Europe, Australia and South America. By using Trialogics’ logistical services, Strados Labs further ensures reliable and timely delivery of RESP Biosensors to study sites globally.
“With Trialogics as a partner, we can confidently expand the reach of our RESP Biosensors to clinical trial sites anywhere in the world,” said Nick Delmonico, CEO of Strados Labs. “Trialogics has demonstrated a successful track record in global logistics for clinical trials and we’re excited to partner with them.”
“We are grateful for the opportunity to grow our relationship with Strados Labs,” said Christopher Gropp, Founder and CEO of Trialogics. “We have worked with Strados Labs previously and been impressed with their technology and mutual desire to improve clinical trials. As clinical trials continue to advance, the need for Strados’ technology and Trialogics’ solutions become more important, making these types of partnerships essential.”
This partnership marks a significant milestone in Strados Labs’ goal to advance respiratory clinical trials on a global scale. Through the collaboration with Trialogics, Strados Labs further ensures the efficient delivery of RESP Biosensors, helping drug developers gain greater, more objective insight into respiratory symptoms alongside patient-reported outcomes.
About Strados Labs
Strados Labs is a medical technology company focused on improving the lives of patients with respiratory disease through innovative technology. Enabling real-world monitoring of lung health, Strados Labs’ RESP Biosensor is a wearable device that allows clinicians to remotely detect changes in patient symptoms such as cough and wheeze that can indicate worsening health. The technology is used to assist clinical trials in the development of new therapies and to support healthcare teams in better managing patients with COPD, Asthma, and other cardiopulmonary diseases. The RESP Biosensor is FDA-cleared, CE marked and HIPAA compliant, backed by multiple awards and clinical publications. Strados Labs is privately owned and based in Philadelphia, PA.
For more information, visit Stradoslabs.com or follow us on LinkedIn and Twitter
About Trialogics
Trialogics is a Delaware-based clinical trial software and logistics company formed in 2015. Since its inception, Trialogics has focused on the decentralization of clinical trials with device management and data integration as key components. Trialogics offers eConsent, IRT/IWRS, eCOA/ePRO, Remote Device Management and global logistics for clinical trials. Trialogics’ services can be utilized individually or as a fully integrated solution. Trialogics is headquartered in Wilmington, Delaware, with offices in London, Rome and Sydney.
For more information, visit trialogics.com or follow us on LinkedIn.
EN 
ES 
FR 
IT 
DE 
PL 
NL 
KO 
TR 
